In-vitro activity of triclosan-eluting ureteral stents against common bacterial uropathogens

Journal of Endourology

Volumn 20, Issue 11, 2006, Pages 949-958

  Chew, Ben H ^a,b   Cadieux, Peter A ^a,b   Reid, Gregor ^a,b   Denstedt, John D ^a,b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Can R and D Ctr for Probiotics   (Canada)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IRGASAN; OUTER MEMBRANE PROTEIN; TRICLOSAN; VIRULENCE FACTOR;

ANTIBIOSIS; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; DEVICE; DRUG ELUTING STENT; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; URETER STENT; URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS, LOCAL; BACTERIA; BACTERIAL ADHESION; BACTERIAL OUTER MEMBRANE PROTEINS; BIOFILMS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FIMBRIAE PROTEINS; HYDROLASES; MICROSCOPY, ELECTRON, SCANNING; PROMOTER REGIONS (GENETICS); STENTS; TRICLOSAN; URETER;

EID: 33845428528     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2006.20.949     Document Type: Article

References (18)

1. Choong S, Whitfield H. Biofilms and their role in infections in urology. BJU Int 2000;86:935-941.
2. Reid G, Denstedt JD, Kang YS, Lam D, Nause C. Microbial adhesion and biofilm formation on ureteral stents in vitro and in vivo. J Urol 1992;148:1592-1594.
3. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature 1998;394:531-532.
4. Bhargava HN, Leonard PA. Triclosan: Applications and safety. Am J Infect Control 1996;24:209-218.
5. Storch M, Scalzo H, Van Lue S, Jacinto G. Physical and functional comparison of Coated VICRYL(r) Plus Antibacterial Suture (coated polyglactin 910 suture with triclosan) with Coated VICRYL(r) Suture (coated polyglactin 910 suture). Surg Infect 2002;3(suppl 1):S65-S77.
6. Storch M, Perry LC, Davidson JM, Ward JJ. A 28-day study of the effect of Coated VICRYL® Plus Antibacterial Suture (coated polyglactin 910 suture with triclosan) on wound healing in guinea pig linear incisional skin wounds. Surg Infect 2002;3(suppl 1):S89-S98.
7. Chew BH, Cadieux PA, Knudsen BE, DeJong K, Rowe E, Reid G, Densted JD. Triclosan loaded ureteral stents reduce Proteus mirabilis 296 infection in a rabbit UTI model. J Urol 2006;175:2331-2335.
8. Brooks T, Keevil CW. A simple artificial urine for the growth of urinary pathogens. Lett Appl Microbiol 1997;24:203-206.
9. Chew BH, Denstedt JD. Technology insight: Novel ureteral stent materials and designs. Nature Clin Pract Urol 2004;1:44-48.
10. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004;109:1942-1947.
11. Choong SK, Wood S, Whitfield HN. A model to quantify encrustation on ureteric stents, urethral catheters and polymers intended for urological use. BJU Int 2000;86:414-421.
12. McMurry LM, Oethinger M. Levy SB. Triclosan targets lipid synthesis. Nature 1998;394:531-532.
13. Heath RJ, Rock CO. A triclosan-resistant bacterial enzyme. Nature 2000;406:145-146.
14. Chuanchuen R, Beinlich K, Hoang TT, Becher A, Karkhoff-Schweizer RR, Schweizer HP. Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: Exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Antimicrob Agents Chemother 2001;45:428-432.
15. McBain AJ, Ledder RG, Sreenivasan P, Gilbert P. Selection for high-level resistance by chronic triclosan exposure is not universal. J Antimicrob Chemother 2004;53:772-777.
16. Braoudaki M, Hilton AC. Low level of cross-resistance between triclosan and antibiotics in Escherichia coli K-12 and E. coli O55 compared to E. coli O157. FEMS Microbiol Lett 2004;235:305-309.
17. Russell AD. Biocide use and antibiotic resistance: The relevance of laboratory findings to clinical and environmental situations. Lancet Infect Dis 2003;3:794-803.
18. Kocazeybek BS. Comparison of the BBL-Mycobacteria Growth Indicator Tube method with culture in the diagnosis of tuberculosis and evaluation of the resistance patterns of isolated strains to four major drugs. Chemotherapy 2002;48:64-70.